Profile of temsirolimus in the treatment of advanced renal cell carcinoma

被引：8
|
作者：
Staehler, Michael [1 ]
Haseke, Nicolas [1 ]
Khoder, Wael [1 ]
Stief, Christian G. [1 ]
机构：
[1] Univ Munich, Dept Urol, Klinikum Grosshadern, D-81377 Munich, Germany
来源：
ONCOTARGETS AND THERAPY | 2010年 / 3卷
关键词：
renal cell cancer; nonclear cell renal cancer; temsirolimus; first-line therapy; overall survival; nephrectomy; INTERFERON-ALPHA; PROGNOSTIC-FACTORS; SURVIVAL; NEPHRECTOMY; CANCER;
D O I：
10.2147/OTT.S7657
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Temsirolimus is a potent inhibtor of the mammalian target of rapamycin (mTOR). In various clinical trials temsirolimus has shown an overall survival benefit for patients with metastatic renal cell carcinoma (mRCC). Thus it is approved for first-line therapy in high-risk mRCC patients. We discuss the indication, side effects and clinical implications of temsirolimus treatment.
引用
收藏
页码：191 / 196
页数：6
相关论文
共 50 条
  • [41] PREDICTORS OF SURVIVAL IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA WHO RECEIVED FIRST LINE TREATMENT WITH TEMSIROLIMUS, INTERFERON-A OR COMBINATION TEMSIROLIMUS/INTERFERON-A
    Mallick, R.
    Chen, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 191 - 191
  • [42] Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-α
    Yang, S.
    de Souza, P.
    Alemao, E.
    Purvis, J.
    BRITISH JOURNAL OF CANCER, 2010, 102 (10) : 1456 - 1460
  • [43] Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-α
    S Yang
    P de Souza
    E Alemao
    J Purvis
    British Journal of Cancer, 2010, 102 : 1456 - 1460
  • [44] Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma
    Cho, Daniel
    Signoretti, Sabina
    Dabora, Sandra
    Regan, Meredith
    Seeley, Apryle
    Mariotti, Mauro
    Youmans, Amanda
    Polivy, Adam
    Mandato, Lucy
    McDermott, David
    Stanbridge, Eric
    Atkins, Michael
    CLINICAL GENITOURINARY CANCER, 2007, 5 (06) : 379 - 385
  • [45] A case of perforated appendicitis during temsirolimus treatment for metastatic renal cell carcinoma
    Yazawa, Satoshi
    Mizuno, Ryuichi
    Kaneko, Gou
    Ochiai, Hiroki
    Oya, Mototsugu
    INTERNATIONAL CANCER CONFERENCE JOURNAL, 2014, 3 (01): : 58 - 60
  • [46] A case of perforated appendicitis during temsirolimus treatment for metastatic renal cell carcinoma
    Satoshi Yazawa
    Ryuichi Mizuno
    Gou Kaneko
    Hiroki Ochiai
    Mototsugu Oya
    International Cancer Conference Journal, 2014, 3 (1) : 58 - 60
  • [47] Safety considerations for temsirolimus (toriseltm a novel inhibitor of mammalian target of rapamycin, in the treatment of patients with advanced renal cell carcinoma
    Roethke, Susan
    ONCOLOGY NURSING FORUM, 2007, 34 (06) : 1245 - 1246
  • [48] Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma
    Venugopal, Balaji
    Ansari, Jawaher
    Aitchison, Michael
    Tho, Lye Mun
    Campbell, Roderick
    Jones, Rob J.
    BMC UROLOGY, 2013, 13
  • [49] Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma
    Motzer, Robert J.
    Hudes, Gary R.
    Curti, Brendan D.
    McDermott, David F.
    Escudier, Bernard J.
    Negrier, Sylvie
    Duclos, Brigitte
    Moore, Laurence
    O'Toole, Timothy
    Boni, Joseph P.
    Dutcher, Janice P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) : 3958 - 3964
  • [50] Temsirolimus controlled metastatic advanced renal cell carcinoma for over 4 years: a case study
    Tatsuya Takayama
    Hiroshi Furuse
    Fumitake Kai
    Takayuki Sugiyama
    Seiichiro Ozono
    Medical Oncology, 2013, 30
12345